Aethlon Medical, Inc.
SAN DIEGO, CA · CIK 0000882291 · Medtech · Public
Hemopurifier, a blood filtration device that removes circulating tumor cells and cancer-related toxins from patient blood
aethlonmedical.com →- Grants
- $2.2M
- 2 awards
- Sector median: 1
- Raised
- $22M
- 18 Form D · Dec 2025
- 9 months since last filing
- Contracts
- $8.1M
- 3 awards · Defense, Health and Human S
- #81 of 4531 in medtech
- Patents
- 38
- 4 granted · 34 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2008201020122014201620182020202220242026
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised· 1 of 2 same day | Form D · SEC | $300,000 | |
| Private capital raised· 2 of 2 same day | Form D · SEC | $307,500 | |
| Private capital raised | Form D · SEC | $600,000 | |
| Private capital raised | Form D · SEC | $890,000 | |
| Private capital raised | Form D · SEC | $650,000 | |
| Private capital raised | Form D · SEC | $350,000 | |
| Federal contract | Department of Defense · Research | $5,935,996 | |
| Private capital raised | Form D · SEC | $210,000 | |
| Private capital raised | Form D · SEC | $1,041,000 | |
| Private capital raised | Form D · SEC | $400,000 | |
| Private capital raised | Form D · SEC | $230,000 | |
| Private capital raised· 1 of 3 same day | Form D · SEC | $837,737 | |
| Private capital raised· 2 of 3 same day | Form D · SEC | $913,500 | |
| Private capital raised· 3 of 3 same day | Form D · SEC | $838,725 | |
| Private capital raised | Form D · SEC | $527,780 | |
| Private capital raised | Form D · SEC | $3,300,000 | |
| Private capital raised | Form D · SEC | $6,000,000 | |
| Federal contract | Department of Health and Human Services · Igf::ot::igf Phase I SBIR Topic 359 Title: Device Strategy For Selective Isolation Of Oncosomes And Non-malignant Exosomes 09/15/2017 - 06/14/2018 Firm Fixed Price | $299,250 | |
| Federal grant | Department of Health and Human Services · Phase I · The Hemopurifier Device for Targeted Removal of Breast Cancer Exosomes from the Blood Circulation | $298,444 | |
| Federal contract | Department of Health and Human Services · Topic 359: A Device Prototype For Isolation Of Melanoma Exosomes For Diagnostics And Treatment Monitoring | $1,860,557 | |
| Private capital raised | Form D · SEC | $2,733,797 | |
| Private capital raised | Form D · SEC | $2,153,700 |
Federal grant · SBIR/STTRFederal contract · USAspendingForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 78 | MYOMO INC | $8.6M | $6.8M |
| 79 | Keranetics, LLC | $8.4M | $9.9M |
| 80 | ViewRay, Inc. | $8.2M | $69M |
| 81 | Aethlon Medical, Inc. | $8.1M | $22M |
| 82 | LIFEWARE LABS LLC | $8.1M | — |
| 83 | QUADRIDOX INC. | $8.0M | — |
| 84 | Personal Genome Diagnostics Inc. | $7.9M | $198M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Franklyn Barry, Jr.Director
- FRANKLYN BARRY, JR.Director
- Edawrd BroennimanDirector
- Edward BroennimanDirector
- EDWARD BROENNIMANDirector
- GUY CIPRIANIDirector
- CHARLES FISHERDirector
- James FrakesDirector · Executive Officer
- JAMES FRAKESExecutive Officer
- Nicolas GikakisDirector
- James JoyceDirector · Executive Officer
- JAMES JOYCEDirector · Executive Officer
- Rodney KenleyDirector · Executive Officer
- RODNEY KENLEYDirector · Executive Officer
- SABRINA MARTUCCI JOHNSONDirector
- TIMOTHY RODELLDirector · Executive Officer
- Angela RossettiDirector
- CHETAN SHAHDirector
- Chetan Shah, MDDirector
- Chetan Shah, M.D.Director
- CHETAN SHAH, MDDirector
- Richard TullisDirector · Executive Officer
- RICHARD TULLISDirector · Executive Officer
- Richard Tullis, PhDDirector · Executive Officer
- RICHARD TULLIS, PhDDirector · Executive Officer
- RICHARD TULLIS, PH.D.Director · Executive Officer
- Richard Tulls, PhDDirector · Executive Officer
- PHILLIP WARDDirector
- THOMAS WORNHAMDirector
Patents
- Devices And Methods For Treating A Coronavirus Infection And Symptoms Thereofgranted
- Devices And Methods For Treating A Viral Infection And Symptoms Thereofapplication
- Method For Removal Of Viruses From Blood By Lectin Affinity Hemodialysisapplication
- Multiplex Cerebrospinal Fluid Processing Systemapplication
- Methods And Compositions For Quantifying Exosomesapplication
- Affinity Capture Of Circulating Biomarkersapplication
- Method For Removal Of Viruses From Blood By Lectin Affinity Hemodialysisapplication
- Affinity Capture Of Circulating Biomarkersapplication
- Method For Removal Of Viruses From Blood By Lectin Affinity Hemodialysisgranted
- Methods For Delivering Regional Citrate Anticoagulation (rca) During Extracorporeal Blood Treatmentsapplication
- Extracorporeal Removal Of Microvesicular Particlesgranted
- Extracorporeal Removal Of Microvesicular Particlesgranted
Regulatory activity · Medtech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.